Inventor · disambiguated record
Christoph Thiemermann
Also filed as: THIEMERMANN CHRISTOPH
6 granted patents·3 pending applications·111 citations·filing 2000–2025
81Inventor score
Files withASSIST PUBLIQUE HOPITAUX DE MARSEILLE2UNIV LONDON QUEEN MARY22N PHARMA APS1CSL BEHRING AG1QUEEN MARY & WESTFIELD COLLEGE UNIV OF LONDON1
Top patents by PatentIndex Score
9 records- 0194US7759315B2Treatment of inflammatory conditions of the intestineCSL BEHRING AG·Filed 2005·Granted Jul 20, 2010·89 cites·16 claims
- 0280US9603831B2Artemisinin and its derivatives for use in the treatment of kidney diseaseQUEEN MARY & WESTFIELD COLLEGE UNIV OF LONDON·Filed 2012·Granted Mar 28, 2017·8 cites·24 claims
- 0377US9623005B2Artemisinin and its derivatives for use in the treatment of trauma haemorrhage and associated conditionsTHIEMERMANN CHRISTOPH·Filed 2012·Granted Apr 18, 2017·7 cites·12 claims
- 0466US6998388B1High density lipoprotein against organ dysfunction following haemorrhagic shockZLB BEHRING AG·Filed 2000·Granted Feb 14, 2006·7 cites·8 claims
- 0566US2025369988A1Cd146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosisASSIST PUBLIQUE HOPITAUX DE MARSEILLE·Filed 2025·Application pending·0 cites
- 0655US2024293424A1Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject2N PHARMA APS·Filed 2022·Application pending·0 cites
- 0751US9949948B2Artemisinin and its derivatives for use in the treatment of trauma haemorrhage and associated conditionsUNIV LONDON QUEEN MARY·Filed 2017·Granted Apr 24, 2018·0 cites·12 claims
- 0850US12411143B2CD146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosisASSIST PUBLIQUE HOPITAUX DE MARSEILLE·Filed 2019·Granted Sep 9, 2025·0 cites·6 claims
- 0945US2019092814A1PeptideUNIV LONDON QUEEN MARY·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christoph Thiemermann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →